Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL470893 | 0.90 | TSHR (0.61) | TSHRIDO1AGXTNAAALMNA | |
| SCHEMBL19460555 | 0.88 | TSHR (0.58) | TSHRIDO1AGXTNAAALMNA | |
| SCHEMBL3821073 | 0.84 | TSHR (0.54) | TSHRIDO1AGXTNAAALMNA | |
| SCHEMBL223907 | 0.82 | TSHR (0.78) | TSHRIDO1AGXTLMNAALDH1A1 | |
| SCHEMBL20423790 | 0.82 | NAAA (0.53) | TSHRIDO1AGXTNAAALMNA | |
| SCHEMBL4180174 | 0.81 | TSHR (0.50) | TSHRNAAALMNA | |
| SCHEMBL23567237 | 0.81 | TSHR (0.50) | TSHRIDO1AGXTNAAALMNA | |
| SCHEMBL70291 | 0.80 | TSHR (0.74) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL53267 | 0.80 | TSHR (0.74) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL3423851 | 0.78 | TSHR (0.42) | TSHRIDO1LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024359-B | Process for preparing alkoxymethyl alkynyl ether compounds having terminal triple bonds | 信越化学工业株式会社 | 2024-06-11 | — | — | CN | disclosed |
| EP-3842406-B1 | PROCESS FOR PREPARING AN ALKOXYMETHYL ALKYNYL ETHER COMPOUND HAVING A TERMINAL TRIPLE BOND | SHINETSU CHEMICAL CO (JP) | 2023-10-11 | — | — | EP | disclosed |
| US-11384041-B2 | Process for preparing an alkoxymethyl alkynyl ether compound having a terminal triple bond | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-07-12 | — | — | US | disclosed |
| US-20210198172-A1 | PROCESS FOR PREPARING AN ALKOXYMETHYL ALKYNYL ETHER COMPOUND HAVING A TERMINAL TRIPLE BOND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-07-01 | — | — | US | disclosed |
| EP-3842406-A1 | PROCESS FOR PREPARING AN ALKOXYMETHYL ALKYNYL ETHER COMPOUND HAVING A TERMINAL TRIPLE BOND | Shin-Etsu Chemical Co., Ltd. (JP) | 2021-06-30 | — | — | EP | disclosed |
| CN-113024359-A | Method for producing alkoxymethyl alkynyl ether compounds having terminal triple bond | 信越化学工业株式会社 | 2021-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198172-A1 | PROCESS FOR PREPARING AN ALKOXYMETHYL ALKYNYL ETHER COMPOUND HAVING A TERMINAL TRIPLE BOND | CBR3, CBR1, AOC2 | TSHR 2045/4885IDO1 3638/4885AGXT 979/4885 |
| US-11384041-B2 | Process for preparing an alkoxymethyl alkynyl ether compound having a terminal triple bond | CBR3, CBR1, AOC2 | TSHR 2045/4885IDO1 3638/4885AGXT 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.